Evidence map›Paper›PMID 37996507›Full record

ArticleBritish journal of cancer2024

Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial.

Hans-Joachim Schmoll, Julia Mann, Fabian Meinert, Benjamin Garlipp, Kersten Borchert, Arndt Vogel, Eray Goekkurt, Ulrich Kaiser, Heinz-Gert Hoeffkes, Jörn Rüssel and 13 more

Registry-linked trialOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01321957 (FOLFOX and Bevacizumab With or Without Irinotecan in First-line Treatment for Metastatic Colorectal Cancer. A Randomized Phase II Study), which is not on this map. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01321957 phase2completednot on this map

FOLFOX and Bevacizumab With or Without Irinotecan in First-line Treatment for Metastatic Colorectal Cancer. A Randomized Phase II Study

TypeinterventionalSponsorMartin-Luther-Universität Halle-WittenbergRan2011 to 2018Enrolled250ConditionsMetastatic Colorectal CancerArmsOxaliplatin, 5FU/LV, Bevacizumab, 5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Targeted therapy in advancedBMJ (Clinical research ed.) · 2025
    Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Treatment sequencing in metastatic colorectal cancer.Contemporary oncology (Poznan, Poland) · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 9 institutions in 2 countries.

Hans-Joachim SchmollClinic for Internal Medicine IV-Hematology/Oncology, University Clinic, Martin-Luther-University, Halle-Wittenberg, Germany.
Julia MannDepartment of Medicine, Hematology and BMT with section Pneumology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Fabian MeinertClinic for Internal Medicine IV-Hematology/Oncology, University Clinic, Martin-Luther-University, Halle-Wittenberg, Germany.
Benjamin GarlippDepartment for Surgery, Oberhavel Kliniken Oranienburg, Oranienburg, Germany.
Kersten BorchertClinic for Oncology/Hematology Klinikum Magdeburg, Magdeburg, Germany.
Arndt VogelClinic for Gastroenterology, Medical University Hannover, Hannover, Germany.ORCID 0000-0003-0560-5538
Eray GoekkurtDepartment of Medicine, Hematology and BMT with section Pneumology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Ulrich KaiserClinic for Hematology/Oncology, St. Bernward Krankenhaus, Hildesheim, Germany.
Heinz-Gert HoeffkesTumorclinic, Klinikum Fulda, Fulda, Germany.
Jörn RüsselClinic for Internal Medicine IV-Hematology/Oncology, University Clinic, Martin-Luther-University, Halle-Wittenberg, Germany.
Stephan KanzlerMedical Clinic II, Leopoldina Clinic Schweinfurt, Schweinfurt, Germany.
Thomas EdelmannOncological Practice Schkeuditz, Schkeuditz, Germany.
Helmut ForstbauerOncological Practice Rheinsieg, Bonn, Germany.
Thomas GöhlerOncological Center Dresden, Dresden, Germany.
Carla HannigOncological Practice Bottrop, Bottrop, Germany.
Bert HildebrandtClinic for Gastroenterology, Hematology and Medical Oncology, Klinikum Barnim, Eberswalde, Germany.
Carsten RollClinic for Oncology/Hematology Klinikum Magdeburg, Magdeburg, Germany.
Carsten BokemeyerDepartment of Medicine, Hematology and BMT with section Pneumology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Jörg SteighardtCoordination Center for Clinical Trials Halle, Medical Faculty, Martin-Luther-University, Halle-Wittenberg, Germany.
Franziska CygonClinic for Internal Medicine IV-Hematology/Oncology, University Clinic, Martin-Luther-University, Halle-Wittenberg, Germany.
Stefan IbachX-act Cologne Clinical Research GmbH, Köln, Germany.
Alexander Stein *Department of Medicine, Hematology and BMT with section Pneumology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Joseph Tintelnot *Department of Medicine, Hematology and BMT with section Pneumology, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. j.tintelnot@uke.de.ORCID 0000-0003-4619-9433
Universität Hamburg · DELuther University · KRKlinikum Magdeburg · DEKlinikum Fulda · DELeopoldina Krankenhaus Schweinfurt · DEMarienhospital Bottrop · DEMartin Luther University Halle-Wittenberg · DEMedizinische Hochschule Hannover · DESt. Bernward Krankenhaus · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFOLFOXIRI plus bevacizumab has demonstrated benefits for metastatic colorectal cancer (mCRC) patients. However, challenges arise in its clinical implementation due to expected side effects and a lack of stratification criteria.

methodsThe AIO "CHARTA" trial randomised mCRC patients into clinical Group 1 (potentially resectable), 2 (unresectable/risk of rapid progression), or 3 (asymptomatic). They received FOLFOX/bevacizumab +/- irinotecan. The primary endpoint was the 9-month progression-free survival rate (PFSR@9). Secondary endpoints included efficacy in stratified groups, QoL, PFS, OS, ORR, secondary resection rate, and toxicity.

resultsThe addition of irinotecan to FOLFOX/bevacizumab increased PFSR@9 from 56 to 67%, meeting the primary endpoint. The objective response rate was 61% vs. 69% (P = 0.21) and median PFS was 10.3 vs. 12 months (HR 0.83; P = 0.17). The PFS was (11.4 vs. 12.9 months; HR 0.83; P = 0.46) in potentially resectable patients, with a secondary resection rate of 37% vs. 51%. Moreover, Group 3 (asymptomatic) patients had a PFS of 11.1 vs. 16.1 months (HR 0.6; P = 0.14). The addition of irinotecan did not diminish QoL.

conclusionThe CHARTA trial, along with other studies, confirms the efficacy and tolerability of FOLFOXIRI/bevacizumab as a first-line treatment for mCRC. Importantly, clinical stratification may lead to its implementation.

trial registrationThe trial was registered as NCT01321957.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsColorectal NeoplasmsBevacizumabHumansIrinotecanQuality of LifeRandomized Controlled Trials as TopicBevacizumabIrinotecan

Identifiers

PMID37996507
PMCPMC10803799
OpenAlexW4388940230

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.